Komori
Astellas Pharma (4503) · InitiativeRestated

Pursuing Strategic Business Investment and Product Introductions

First written in FY2016. 1 of 2 entries say "Restated". Latest entry: FY2017.

2entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY20172016: 120162017: 12017
Same theme, other companies
Continued Growth Through Strategic Investment, Quality Improvement, and GlobalizationA theme 7 companies write about · 0 as a headwind · 7 as a tailwind

2 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2017RestatedAnnual report

    「また、製品ラインを一層強化するため、グローバル並びにローカルレベルで積極的に製品導入を図る等、様々な戦略的事業投資機会を追求していきます。」

    製品ライン強化のため、地域横断的な製品導入と戦略的事業投資を追求する方針を維持している。
  2. FY2016First statedAnnual report

    「また、製品ラインを一層強化するため、グローバルならびにローカルレベルで積極的に製品導入を図るなど、様々な戦略的事業投資機会を追求していきます。」

    製品ライン強化の手段として、地域レベルの製品導入と戦略的投資機会を挙げている。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.